US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Veraxa Biotech Holding AG

1.95

+0.06003.17%

Post-market: 1.950.00000.00%19:02 EDT

Volume:80.15K

Turnover:155.63K

Market Cap:275.75M

PE:9.10

High:2.00

Open:1.86

Low:1.85

Close:1.89

52wk High:27.36

52wk Low:1.70

Shares:141.41M

Float Shares:41.01M

Volume Ratio:0.97

T/O Rate:0.20%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2142

ROE:-65.29%

ROA:-20.46%

PB:7.11

PE(LYR):- -

Loading ...

Overview Company News Filings

Why VERAXA Biotech (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D

Veraxa Collaborates With Ardigen to Use AI for Cancer Drug Development

MT Newswires Live

Veraxa Biotech to Launch Ai-enabled Drug Discovery Collaboration with Ardigen to Support Growing Bitac® Pipeline

THOMSON REUTERS

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday

Benzinga Earnings

Veraxa Biotech Names Carl Von Halem Interim CFO, Replacing Torsten Bürgermeister

Veraxa CFO Torsten Burgermeister steps down, Carl von Halem named interim CFO

Veraxa Biotech Ag Appoints Carl Von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister

THOMSON REUTERS

VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition

Veraxa Biotech Proposes Raising Conditional Capital Ceiling to CHF 459,789 Via Bylaw Change

VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

Veraxa Biotech provides pipeline and partnering strategy update

Veraxa Biotech Ag - Targets Vxa-102 Ind/cta-ready by Beginning of 2028

THOMSON REUTERS

Veraxa Biotech Ag - to Focus Investments on Bitac Portfolio and Monetize Non-bitac Assets

THOMSON REUTERS

Veraxa Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines

THOMSON REUTERS

VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines

VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program

Veraxa Collaborates With ATUM on Cell Line Development for BiTAC T-Cell Engager Program

MT Newswires Live

Veraxa Biotech Initiates Cell Line Development with Atum to Advance Its Lead Bitac®-tce Program

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/VRXA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.95,"timestamp":1787342400000,"preClose":1.89,"halted":0,"volume":80147,"hourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":1.95,"latestTime":"19:02 EDT","volume":146,"amount":283.17,"timestamp":1787353358074,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03174603174603178,"floatShares":41012504,"shares":141407813,"eps":0.2142,"marketStatus":"Market Closed","change":0.06,"latestTime":"08-21 16:00:00 EDT","open":1.86,"high":2,"low":1.8501,"amount":155628,"amplitude":0.079312,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.89,"preHourTrading":{"tag":"盘前","latestPrice":1.87,"preClose":1.89,"latestTime":"09:27 EDT","volume":304,"amount":569.2840192,"timestamp":1787318870054,"change":-0.02,"changeRate":-0.010582,"amplitude":0.015873},"postHourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":1.95,"latestTime":"19:02 EDT","volume":146,"amount":283.17,"timestamp":1787353358074,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.967295187072036},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":41012504,"roa":"-20.46%","roe":"-65.29%","lyrEps":0,"volumeRatio":0.967295187072036,"shares":141407813,"dividePrice":0,"high":2,"amplitude":0.079312,"preClose":1.89,"low":1.8501,"week52Low":1.7,"pbRate":"7.11","week52High":27.36,"institutionHeld":0,"latestPrice":1.95,"eps":0.2142,"divideRate":0,"volume":80147,"delay":0,"ttmEps":0.2142,"open":1.86,"prevYearClose":18.65,"prevWeekClose":1.87,"prevMonthClose":1.76,"prevQuarterClose":1.88,"fiveDayClose":1.87,"twentyDayClose":1.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-08-21","current":9.103641,"percent":0,"low":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"high":-1.331869,"avg":-1.34261,"sd":0.010741,"marketCap":47660725},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725}],"updateTime":1787535508555},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651460997","title":"Why VERAXA Biotech (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2651460997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651460997?lang=en_us&edition=fundamental","pubTime":"2026-07-16 01:30","pubTimestamp":1784136642,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 15th, 2026, FinanceWire Artificial intelligence is becoming an increasingly important tool for drug discovery, w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/why-veraxa-biotech-nasdaq-vrxa-could-benefit-more-than-others-from-ais-growing-impact-on-drug-rd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/why-veraxa-biotech-nasdaq-vrxa-could-benefit-more-than-others-from-ais-growing-impact-on-drug-rd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIW.SI","AIPO","MNQmain","QDTE","BK4581","CHAT","NQmain","QLD","JEPQ","XBI",".IXIC","QQQJ","SQQQ","QQQA","BK4588","QID","TQQY","AGIX","QYLG","QQQM","FTEC","TQQQ","VTHR","PSQ","QTOC","BK4139","VRXA","TECS","QQQE","QQQY","ONEQ","QQQ","BK4585","NDX","ARTY","GPIQ","IYW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651023119","title":"Veraxa Collaborates With Ardigen to Use AI for Cancer Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2651023119","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651023119?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:14","pubTimestamp":1783944865,"startTime":"0","endTime":"0","summary":"Veraxa Biotech  said Monday it is collaborating with Ardigen to use artificial intelligence to advance its BiTAC cancer therapy pipeline.The partnership will initially focus on developing AI tools to identify and prioritize dual-target combinations for Veraxa's bispecific T-cell engagers and antibody-drug conjugates, it said.The company said its BiTAC platform uses an \"AND-gate\" approach that activates when two cancer targets are present on the same cell, a strategy designed to reduce off-target toxicity and improve treatment precision.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CHAT","QTOC","AGIX","ARTY","VRXA","AIPO","BK4139","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115682","title":"Veraxa Biotech to Launch Ai-enabled Drug Discovery Collaboration with Ardigen to Support Growing Bitac® Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115682?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:00","pubTimestamp":1783940400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA89CKY9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115444","title":"VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115444","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115444?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:00","pubTimestamp":1783940400,"startTime":"0","endTime":"0","summary":"Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs)ZURICH, SWITZERL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/13/3326056/0/en/VERAXA-Biotech-to-Launch-AI-enabled-Drug-Discovery-Collaboration-with-Ardigen-to-Support-Growing-BiTAC-Pipeline.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","XBI","ARTY","AGIX","BK4581","CHAT","AIPO","VRXA","VTHR","QTOC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651819687","title":"FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2651819687","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651819687?lang=en_us&edition=fundamental","pubTime":"2026-07-13 14:35","pubTimestamp":1783924558,"startTime":"0","endTime":"0","summary":"U.S. stock futures down today, FB Financial, Smith Micro Software, LogProstyle, Veraxa Biotech, and Q32 Bio among stocks to watch. More premarket coverage at Benzinga.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/07/60406840/fb-financial-smith-micro-software-and-3-stocks-to-watch-heading-into-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGPS","SMSI","QTTB","VRXA","BK4023","BK4139","BK4211","BK4024","FBK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650137343","title":"Veraxa Biotech Names Carl Von Halem Interim CFO, Replacing Torsten Bürgermeister","url":"https://stock-news.laohu8.com/highlight/detail?id=2650137343","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650137343?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:22","pubTimestamp":1783714941,"startTime":"0","endTime":"0","summary":"Veraxa Biotech names Carl von Halem interim CFO, replacing Torsten BürgermeisterVeraxa appointed Carl von Halem as interim chief financial officer, replacing Torsten Bürgermeister.Management is in lat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL7g0x3j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650137360","title":"Veraxa CFO Torsten Burgermeister steps down, Carl von Halem named interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2650137360","media":"TIPRANKS","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650137360?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:10","pubTimestamp":1783714212,"startTime":"0","endTime":"0","summary":"Veraxa Biotech (VRXA) announced the appointment of Carl von Halem as interim CFO. He succeeds Torsten Burgermeister. The company is currently in th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veraxa-cfo-torsten-burgermeister-steps-down-carl-von-halem-named-interim-cfo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veraxa-cfo-torsten-burgermeister-steps-down-carl-von-halem-named-interim-cfo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","XBI","BK4588","CFO","BK4139","VRXA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650132783","title":"Veraxa Biotech Ag Appoints Carl Von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister","url":"https://stock-news.laohu8.com/highlight/detail?id=2650132783","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650132783?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:05","pubTimestamp":1783713900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nTUA8QNSV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650975096","title":"VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2650975096","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650975096?lang=en_us&edition=fundamental","pubTime":"2026-07-10 01:00","pubTimestamp":1783616408,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 9th, 2026, FinanceWire The company has initiated cell line development for its lead BiTAC(R) T-cell engager prog...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-lead-bitacr-t-cell-engager-program-with-cell-line-development-partnership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-lead-bitacr-t-cell-engager-program-with-cell-line-development-partnership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","QQQJ","QID","ONEQ","TQQY","MNQmain","NVIW.SI","QDTE","QQQA","TQQQ","R","BK4022","VRXA","BK4232","QQQ",".IXIC","IYW","QQQM","BK4139","QQQE","QYLG","QLD","QQQY","FTEC","NQmain","DBB","SQQQ","XBI","PSQ","NDX","TECS","GPIQ","BK4581","JEPQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649931305","title":"VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2649931305","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649931305?lang=en_us&edition=fundamental","pubTime":"2026-07-08 00:30","pubTimestamp":1783441807,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 7th, 2026, FinanceWire Novartis has agreed to acquire Myricx Bio for $1.1 billion upfro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-shareholders-should-watch-novartis-latest-1-5b-adc-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-shareholders-should-watch-novartis-latest-1-5b-adc-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ","NDX","QQQA","IYW","QQQ","BK4588","QQQE","NETL","QLD","TQQQ","BK4231","ADC","QID","XBI","MNQmain","TQQY","JEPQ","NQmain","SQQQ","GPIQ","NVIW.SI","BK4581","VRXA","QYLG","QQQM","QQQJ","TECS","ONEQ","BK4139","QDTE","FTEC","QQQY",".IXIC","BK4585","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649291679","title":"Veraxa Biotech Proposes Raising Conditional Capital Ceiling to CHF 459,789 Via Bylaw Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2649291679","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649291679?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:11","pubTimestamp":1783368675,"startTime":"0","endTime":"0","summary":"Veraxa Biotech proposes raising conditional capital ceiling to CHF 459,789 via bylaw changeVeraxa Biotech set a July 24, 2026 extraordinary shareholder vote on bylaw changes expanding its equity issua","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDLblPcHf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649753526","title":"VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2649753526","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649753526?lang=en_us&edition=fundamental","pubTime":"2026-07-07 01:00","pubTimestamp":1783357208,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 6th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) provided a corporate and pipeline update highlighting p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-highlights-bitac-pipeline-progress-advances-partnering-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-highlights-bitac-pipeline-progress-advances-partnering-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","QYLG","TQQQ",".IXIC","NDX","FTEC","TECS","XBI","IYW","JEPQ","QLD","BK4581","BK4588","TQQY","PSQ","SQQQ","QQQJ","BK4585","BK4139","QDTE","NVIW.SI","GPIQ","QQQM","QID","MNQmain","QQQY","QQQ","QQQE","LU2065732104.USD","QQQA","VRXA","BK4097","ONEQ","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649242006","title":"Veraxa Biotech provides pipeline and partnering strategy update","url":"https://stock-news.laohu8.com/highlight/detail?id=2649242006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649242006?lang=en_us&edition=fundamental","pubTime":"2026-07-06 21:15","pubTimestamp":1783343707,"startTime":"0","endTime":"0","summary":"Veraxa Biotech (VRXA) provided a company and pipeline update, highlighting its strategic focus on its proprietary BiTAC platform. The company inten...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-provides-pipeline-and-partnering-strategy-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-provides-pipeline-and-partnering-strategy-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","XBI","VRXA","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649625646","title":"Veraxa Biotech Ag - Targets Vxa-102 Ind/cta-ready by Beginning of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2649625646","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649625646?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:00","pubTimestamp":1783335602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA5CXFFC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649625627","title":"Veraxa Biotech Ag - to Focus Investments on Bitac Portfolio and Monetize Non-bitac Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2649625627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649625627?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:00","pubTimestamp":1783335602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA5CXFFC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649256786","title":"Veraxa Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2649256786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649256786?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:00","pubTimestamp":1783335602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA5CXFFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649267546","title":"VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2649267546","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649267546?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:00","pubTimestamp":1783335600,"startTime":"0","endTime":"0","summary":"Novel conditionally active T cell engagers sourced from proprietary BiTAC platform are at the basis of advanced partnering initiatives and development activitiesZURICH, SWITZERLAND – July 6, 2026 -- V","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/06/3322298/0/en/VERAXA-Biotech-Provides-Business-Update-and-Further-Details-on-Partnering-Strategy-and-Development-Timelines.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","VRXA","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648368411","title":"VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648368411","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648368411?lang=en_us&edition=fundamental","pubTime":"2026-07-03 01:00","pubTimestamp":1783011614,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 2nd, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) announced the initiation of cell line development for i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-initiates-cell-line-development-for-lead-bitac-cancer-therapy-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-initiates-cell-line-development-for-lead-bitac-cancer-therapy-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ","VRXA","QDTE","QLD","XBI","TECS","SQQQ","TQQY","TQQQ","QQQE","QQQY","QID","BK4585","QQQA","NVIW.SI","BK4588","NQmain","QQQ","GPIQ","MNQmain","FTEC","JEPQ","NDX","ONEQ","BK4139","QQQJ","BK4581","QYLG","QQQM","IYW",".IXIC","DBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648040085","title":"Veraxa Collaborates With ATUM on Cell Line Development for BiTAC T-Cell Engager Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648040085","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648040085?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:39","pubTimestamp":1782992371,"startTime":"0","endTime":"0","summary":"Veraxa Biotech  said Thursday it has engaged US contract research organization ATUM to begin cell line development for its lead BiTAC T-cell engager program.The company said ATUM will support the generation of stable clonal cell lines using its Leap-In Transposase technology.The company said the cell lines will be used throughout CMC development, including early process, analytical testing, formulation work, and production of material for nonclinical studies.Veraxa said its BiTAC-TCE platform is designed to improve the safety of T-cell engager therapies by activating T-cells only when two tumor markers are present on the same cell, reducing the risk of attacking healthy tissue.Shares of Veraxa Biotech were up more than 3% in premarket activity Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648014435","title":"Veraxa Biotech Initiates Cell Line Development with Atum to Advance Its Lead Bitac®-tce Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648014435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648014435?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:00","pubTimestamp":1782990017,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nFWN4340EX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":62,"code":"91000000","status":"200"}]}}